Navigation Links
EnVivo Pharmaceuticals Announces Significant Results from GSM Transgenic Mouse Model for Alzheimer's Disease
Date:7/14/2010

HONOLULU, July 14 /PRNewswire/ -- EnVivo Pharmaceuticals today announced at the Alzheimer's Association 2010 International Conference on Alzheimer's Disease (ICAD) results from its proprietary gamma-secretase modulator (GSM) pre-clinical study.  In a transgenic mouse model, EnVivo's EVP-0015962 reduced amyloid plaque buildup which is believed to be a cause of Alzheimer's disease, reversed behavioral deficits and reduced brain inflammation associated with Alzheimer's disease.

EVP-0015962 is a proprietary small molecule compound that belongs to a new generation of potential Alzheimer's drugs known as gamma-secretase modulators.  EVP-0015962 selectively inhibits the production of the toxic aggregated amyloid AB42 peptide without affecting the total amount of AB.  As EVP-0015962 does not affect other gamma secretase substrates required for normal function, such as Notch, it is predicted to slow the progression of Alzheimer's disease by reducing the disease-associated toxic AB42 species.

In its study, EnVivo was able to show that EVP-0015962 significantly reduced the production of total amyloid load as measured by plaque count, surface area and aggregated AB in the brains of transgenic mice after 12 months of daily oral administration.  In the same model, mice developed deficits in the hippocampal memory task known as contextual fear conditioning.  Chronic dosing with EVP-0015962 reversed these deficits returning the cognitive function to normal levels.  In addition, EVP-0015962 reduced the amount of brain inflammation associated with amyloid plaque buildup in these animals.

These findings demonstrate continued positive effects in transgenic Alzheimer's animals with EVP-0015962.  Given the multiple positive results from this and previous studies, EnVivo is confid
'/>"/>

SOURCE EnVivo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. EnVivo Pharmaceuticals Announces Progress on Major Drug Programs Focusing on Alzheimers, Schizophrenia and Huntingtons Diseases
2. EnVivo Pharmaceuticals Announces Initiation of Clinical Safety and Biomarker Study of Alpha-7 Nicotinic Agonist, EVP-6124, in Patients with Schizophrenia
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/hcb7bz/pharmaceutical ) has announced ... UK - November 16-18, 2015)" conference to their offering. ... including Columbia, Peru , Brazil ... Uruguay , Paraguay , Venezuela ... , Chile This seminar can be ...
(Date:9/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/cnq7tc/medical_device ) has ... Studies: Clinical Evidence (London, UK - November 10-11, ... This course has been designed specifically for ... required for medical devices and in-vitro diagnostic products. ... and the emphasis on high quality, appropriate clinical ...
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/r6wspz/drug_delivery_in ) ... report "Drug Delivery in Central Nervous System ... their offering. Advances in understanding ... opened new avenues and possibilities for improved drug ... systems, enzymes, and receptors that control the penetration ...
Breaking Medicine Technology:Pharmaceutical Regulatory Affairs in Latin America Seminar - London, UK - November 16-18, 2015 2Medical Device Studies: Clinical Evidence Course - London, UK - November 10-11, 2015 2Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies Report 2015-2024 2Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies Report 2015-2024 3
... Broadspire, a Crawford Company (NYSE: CRDA ; CRDB) ... provider, is proud to announce that Gary Anderberg, Ph.D., practice ... of Risk & Insurance magazine,s 2010 Risk Innovator ... a leader with Broadspire,s e-Triage system, which helps analyze claims ...
... Pa., Sept. 15 The GBS /CIDP ... symposium on Guillain-Barre Syndrome (GBS) and Chronic Inflammatory ... 5-7, 2010.  Over 400 medical professionals, current and former ... expected to attend the three-day event at the Dolce ...
Cached Medicine Technology:Broadspire’s Gary Anderberg Named a 2010 Risk Innovator 2Broadspire’s Gary Anderberg Named a 2010 Risk Innovator 3GBS/CIDP Foundation to Hold 11th International Symposium 2
(Date:9/3/2015)... ... September 03, 2015 , ... ... triggering cost increases for fully insured employer-sponsored health insurance plans, more employers are ... employees), according to data released from the 2014 United Benefit Advisors (UBA) Health ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... endpoint data collection, cloud analytics and workflow solutions today announced the complete ... Portugal, September 22-24, 2015. The esteemed faculty of worldwide pharmaceutical and industry ...
(Date:9/3/2015)... ... , ... AvePoint, the established leader in enabling enterprise collaboration across ... – AvePoint’s solution for facilitating two-way collaboration and external sharing without ever having to ... is the fifth consecutive year an AvePoint product has made the list. , The ...
(Date:9/3/2015)... ... September 03, 2015 , ... The new In-Office ... of Provo, Utah. The Clinicians Report is a leading information source to the ... throughout the U.S. Whiter Image's In-Office whitening kits were favorably validated for use ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... Local filmmakers ... April Hannah & Michael Habernig from Path 11 Productions have had great success in ... age podcast has featured Hay House authors, Teal Swan who is the well known ...
Breaking Medicine News(10 mins):Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 2Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 3Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 4Health News:ERT Announces Final Agenda, Faculty for European PRO / eCOA Congress 2Health News:ERT Announces Final Agenda, Faculty for European PRO / eCOA Congress 3Health News:AvePoint Perimeter Named a “KMWorld 2015 Trend-Setting Product” 2Health News:AvePoint Perimeter Named a “KMWorld 2015 Trend-Setting Product” 3Health News:AvePoint Perimeter Named a “KMWorld 2015 Trend-Setting Product” 4Health News:Whiter Image Products Get Positive Rating From The Clinicians Report 2Health News:Path 11 Podcast Now Features over 20 Metaphysical Discussions on iTunes and Growing 2Health News:Path 11 Podcast Now Features over 20 Metaphysical Discussions on iTunes and Growing 3
... may be able to help people// suffering from fibromyalgia. ... of Florida the cough medicine seemed to bring relief ... from fibromyalgia. ,Fibromyalgia syndrome occurs with extensive musculo-skeletal ... this diseases. More women than men report to be ...
... that asthmatic women have tendency of// irregular menstruation. ... severe stress, serious disease, anorexia nervosa, and drug addiction. ... women for 8 years to understand the possible link ... the research said that younger women with asthma and ...
... Scientists said that the problem of inability to read ... in visual processes as was thought in recent years. ... of perception than anything else. ,Dyslexia is one ... children, who have difficulty in verbal skills, abstract reasoning, ...
... researchers have established the association between adult urinary incontinence ... than 1000 Turkish women, the research says that the ... same for exhibiting lack of control in controlling urine ... may suffer from some faulty neural pathway that connects ...
... apnea syndrome affects a lot of people who are ... of having a difficult night, these people may have ... ,Obstructive sleep apnea syndrome (OSAS), also known as the ... problems, stroke, obesity, breathing problems, sexual dysfunction and clinical ...
... Women who had been diagnosed with breast cancer need to ... with lowering of levels of ovarian hormones and this could ... cancer patients who regularly exercised for about an hour daily. ... Health Study who were diagnosed with breast cancer of stages ...
Cached Medicine News:
... The Eppendorf Mastercycler Family offers fast temperature ... for optimal flexibility. Personal cards enable safe ... reliable transfer of individual protocols between different ... for PCR and come with a two-year ...
96 well thermocycler with unique High Temperature Range (HTR) Peltier technology for fastest available heating and cooling rates up to 4C/sec with High Pressure Lid for automated sealing of PCR plate...
... 40 or 96 temperature cyclers, the gradient block ... range of up to 14 or 22 across ... temperature difference of up to 2C between adjacent ... test up to 12 different annealing temperatures in ...
... performance, high sample throughput instrument at a highly ... Flexible block format, a newly designed flexible heated ... Includes a four year or 80,000 Cycle Warranty! ... connected and run through a PC using Gensoft, ...
Medicine Products: